GLP-1

Glucagon-Like Peptide-1 (GLP-1) is a 30/31-amino acid peptide hormone primarily secreted by the intestinal L-cells in response to nutrient ingestion. This incretin hormone plays a crucial role in glucose homeostasis by enhancing insulin secretion in a glucose-dependent manner, thereby reducing the risk of hypoglycemia. GLP-1 exerts its action by binding to the GLP-1 receptor, a G-protein coupled receptor found in various tissues, including the pancreas, brain, and gastrointestinal tract. The activation of these receptors not only stimulates insulin release but also inhibits glucagon secretion, delays gastric emptying, and promotes satiety, making it a valuable target for type 2 diabetes management.

The journey of GLP-1 from its discovery to clinical application has been marked by numerous clinical trials. One pivotal study was the LEAD (Liraglutide Effect and Action in Diabetes) series, which demonstrated the efficacy of GLP-1 receptor agonists in improving glycemic control (PMID: 18556324). Another significant trial, the SUSTAIN-6, assessed cardiovascular outcomes with the GLP-1 receptor agonist semaglutide, showcasing its benefits beyond glycemic control (PMID: 27633186).

Pharmacokinetically, native GLP-1 has a short half-life of approximately 1-2 minutes due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). This limitation led to the development of DPP-4 resistant GLP-1 receptor agonists, such as exenatide and liraglutide, which have longer half-lives and are more suitable for therapeutic use. These agents maintain prolonged receptor activation, providing effective glycemic control and weight reduction benefits.

In the current therapeutic landscape, GLP-1 receptor agonists are primarily used for the management of type 2 diabetes and obesity. They are often chosen for their dual benefit of glycemic control and weight loss, an advantage over many traditional antidiabetic agents. Additionally, some GLP-1 receptor agonists have shown cardiovascular benefits, leading to their use in patients with both diabetes and cardiovascular risk factors.

Future research directions for GLP-1 include exploring its role in neuroprotection and potential benefits in treating neurodegenerative diseases such as Alzheimer's. The ongoing EXSCEL trial (PMID: 28845751) further investigates the cardiovascular safety and efficacy of exenatide, broadening the scope of GLP-1's therapeutic potential.

## Key PubMed References 1. LEAD-3 Mono: Liraglutide as Monotherapy for Type 2 Diabetes - PMID: 18556324 2. SUSTAIN-6: Semaglutide and Cardiovascular Outcomes - PMID: 27633186 3. EXSCEL: Exenatide Study of Cardiovascular Event Lowering - PMID: 28845751